TY - JOUR
T1 - Drug development of MET inhibitors
T2 - Targeting oncogene addiction and expedience
AU - Comoglio, Paolo M.
AU - Giordano, Silvia
AU - Trusolino, Livio
PY - 2008/6
Y1 - 2008/6
N2 - The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can also be genetically selected for the long-term maintenance of the primary transformed phenotype, and some tumours appear to be dependent on (or 'addicted' to) sustained MET activity for their growth and survival. Because of its dual role as an adjuvant, pro-metastatic gene for some tumour types and as a necessary oncogene for others, MET is a versatile candidate for targeted therapeutic intervention. Here we discuss recent progress in the development of molecules that inhibit MET function and consider their application in a subset of human tumours that are potentially responsive to MET-targeted therapies.
AB - The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can also be genetically selected for the long-term maintenance of the primary transformed phenotype, and some tumours appear to be dependent on (or 'addicted' to) sustained MET activity for their growth and survival. Because of its dual role as an adjuvant, pro-metastatic gene for some tumour types and as a necessary oncogene for others, MET is a versatile candidate for targeted therapeutic intervention. Here we discuss recent progress in the development of molecules that inhibit MET function and consider their application in a subset of human tumours that are potentially responsive to MET-targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=44449151030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44449151030&partnerID=8YFLogxK
U2 - 10.1038/nrd2530
DO - 10.1038/nrd2530
M3 - Article
C2 - 18511928
AN - SCOPUS:44449151030
VL - 7
SP - 504
EP - 516
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
SN - 1474-1776
IS - 6
ER -